Molecular pathways: Fatty acid synthase

Clinical Cancer Research

Volumn 21, Issue 24, 2015, Pages 5434-5438

  Jones, Suzanne F ^a   Infante, Jeffrey R ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; GSK 2194069; IPI 9119; JNJ 54302833; LIPID; TVB 2640; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; BIOSYNTHESIS; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CYTOLOGY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; MOLECULAR BIOLOGY; MONOTHERAPY; NON SMALL CELL LUNG CANCER; NONHUMAN; PERITONEUM CANCER; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; LIPID METABOLISM; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; TRANSLATIONAL RESEARCH;

ANIMALS; ANTINEOPLASTIC AGENTS; FATTY ACID SYNTHASES; HUMANS; LIPID METABOLISM; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84954110052     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0126     Document Type: Article

References (44)

1. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007;7:763-77.
2. Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res 1953;13:27-9.
3. Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J 2012;279: 2610-23.
4. Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 2010;6:551-62.
5. Chirala SS, Chang H, Matzuk M, Abu-Elheiga L, Mao J, Mahon K, et al. Fatty acid synthesis is essential in embryonic development: fatty acid synthase null mutants and most of the heterozygotes die in utero. Proc Natl Acad Sci U S A 2003;100:6358-63.
6. Pizer ES, Kurman RJ, Pasternack GR, Kuhajda FP. Expression of fatty acid synthase is closely linked to proliferation and stromal decidualization in cycling endometrium. Int J Gynecol Pathol 1997;16:45-51.
7. Maningat PD, Sen P, Rijnkels M, Sunehag AL, Hadsell DL, Bray M, et al. Gene expression in the human mammary epithelium during lactation: the milk fat globule transcriptome. Physiol Genomics 2009;37:12-22.
8. Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, et al. "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab 2005;1:309-22.
9. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A 1994;91:6379-83.
10. Walter K, Hong SM, Nyhan S, Canto M, Fedarko N, Klein A, et al. Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev 2009;18:2380-5.
11. Witkiewicz AK, Nguyen KH, Dasgupta A, Kennedy EP, Yeo CJ, Lisanti MP, et al. Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: implications for tumor progression and clinical outcome. Cell Cycle 2008;7:3021-5.
12. Alo PL, Amini M, Piro F, Pizzuti L, Sebastiani V, Botti C, et al. Immunohistochemical expression and prognostic significance of fatty acid synthase in pancreatic carcinoma. Anticancer Res 2007;27:2523-7.
13. Long QQ, Yi YX, Qiu J, Xu CJ, Huang PL. Fatty acid synthase (FASN) levels in serum of colorectal cancer patients: correlation with clinical outcomes. Tumour Biol 2014;35:3855-9.
14. Cai Y, Wang J, Zhang L, Wu D, Yu D, Tian X, et al. Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer. Med Oncol 2014;32:391.
15. Di Vizio D, Adam RM, Kim J, Kim R, Sotgia F, Williams T, et al. Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. Cell Cycle 2008;7:2257-67.
16. Vazquez-Martin A, Colomer R, Brunet J, Lupu R, Menendez JA. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif 2008;41:59-85.
17. Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, et al. Fatty acid synthase: ametabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 2009;101:519-32.
18. Wooster RF. The molecular consequences of inhibiting fatty acid synthase in cancer cells [abstract]. In: Proceedings of the 11th Annual Congress on Targeted Therapies (TAT 2013); 2013 Mar 4-6; Paris, France. Ann Oncol 2013;24 Suppl 1:i11. Abstract nr L05.03.
19. Chen HW, Chang YF, Chuang HY, Tai WT, Hwang JJ. Targeted therapy with fatty acid synthase inhibitors in a human prostate carcinoma LNCaP/tk-luc-bearing animal model. Prostate Cancer Prostatic Dis 2012;15:260-4.
20. Wang TF, Wang H, Peng AF, Luo QF, Liu ZL, Zhou RP, et al. Inhibition of fatty acid synthase suppresses U-2 OS cell invasion and migration via downregulating the activity of HER2/PI3K/AKT signaling pathway in vitro. Biochem Biophys Res Commun 2013;440:229-34.
21. Fiorentino M, Zadra G, Palescandolo E, Fedele G, Bailey D, Fiore C, et al. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest 2008;88:1340-48.
22. Ventura R, Mordec K, Waszczuk J, Wang Z, Lai J, Fridlib M, et al. Inhibition of de novo palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cellmembranes, inhibiting signaling pathways, and reprogramming gene expression. E Bio Medicine 2015;2:806-22.
23. Benjamin DI, Li DS, Lowe W, Heuer T, Kemble G, Noruma DK. Diacylglycerol metabolism and signaling is a driving force underlying FASN inhibitor sensitivity in cancer cells. ACS Chem Biol 2015;10:1616-23.
24. Menendez JA. Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives. Biochim Biophys Acta 2010;1801:381-91.
25. Zhou W, Simpson PJ, McFadden JM, Townsend CA, Medghalchi SM, Vadlamudi A, et al. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res 2015;63:7330-7.
26. Hardwicke MA, Rendina AR, Williams SP, Moore ML, Wang L, Krueger JA, et al. A human fatty acid synthase inhibitor binds b-ketoacyl reductase in the keto-substrate site. Nat Chem Biol 2014;10:774-9.
27. Lu T, Alexander R, Bignan G, Bischoff J, Connolly P, Cummings M, et al., Design and synthesis of a series highly potent and bioavailable FASN KR domain inhibitors for cancer [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4747.
28. Brophy E, Conley J, O'Hearn P, Douglas M, Cheung C, Coco J, et al., Pharmacological target validation studies of fatty acid synthase in carcinoma using the potent, selective and orally bioavailable inhibitor IPI-9119 [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl): Abstract nr 1891.
29. Patel M, Infante J, Von Hoff D, Jones S, Burris H, Brenner A, et al., Report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT203.
30. O'Farrell M, Crowley R, Heuer T, Buckley D, Rubino CM, McCulloch W, et al., Biomarker and PK/PD analyses of first-in-class FASN inhibitor TVB-2640 in a first-in-human phase 1 study in solid tumor patients [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2675.
31. Arkenau HT, Voskoboynik M, Infante J, Brenner A, Patel M, Borazanci E, et al., Evidence of activity of a new mechanism of action (MoA): a first-inhuman study of the first-in-class fatty acid synthases (FASN) inhibitor, TVB-2640, as monotherapy or in combinations [abstract]. In: Proceedings of the European Cancer Congress; 2015 Sep 25-29; Vienna, Austria. Brussels (Belgium): European Cancer Organisation; 2015. Abstract 27LBA.
32. Champman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
33. Camidge DR, Bang Y-J, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-smallcell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-9.
34. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
35. Menendez JA, Lupu R, Colomer R. Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER-2 neu-overexpressing human breast cancer cells to docetaxel (taxotere). Breast Cancer Res Treat 2004;84:183-95.
36. Menendez JA, Vellon L, Colomer R, Lupu R. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)- induced cytotoxicity. Int J Cancer 2005;115:19-35.
37. Heuer TS, Ventura R, Mordec K, Lai J, Waszczuk J, Hammonds G, et al., Discovery of tumor types highly susceptible to FASN inhibition and biomarker candidates for clinical analysis [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4446.
38. Meena AS, Sharma A, Kumari R, Mohammad N, Singh SV, Bhat MK. Inherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involved. PLoS One 2013;8:e61524.
39. Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S, et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res 2010;70:8117-26.
40. Alwarawrah Y, Hughes P, Safi R, McDonnell DP, Spector NL, Haystead TA. Overcoming lapatinib resistance by the fatty acid synthase inhibitor HS-106 [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; 2015. Abstract nr 2703.
41. de Botton S, Pollyea DA, Stein EM, DiNardo C, Fathi AT, Roboz GJ, et al., Clinical safety and activity of AG-120, a first-in-class potent inhibitor of the IDH1 mutant protein, in a phase 1 study of patients with advanced, IDH1-mutant hematological malignancies [abstract]. In: Proceedings of the 20th Congress of the European Hematology Association; 2015 Jun 11-14; Vienna, Austria. The Hague (the Netherlands): EHA; 2015. Abstract nr P563.
42. Stein EM, Altman JK, Collins R, DeAngelo DJ, Fathi AT, Flinn I, et al., AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase I study in patients with IDH2 mutation positive advanced hematologic malignancies [abstract]. In: Proceedings of the 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, CA. Washington (DC): American Society of Hematology; 2014. Abstract nr 115.
43. Harding JJ, Telli ML, Munster PN, Le MH, Molineaux C, Bennett MK, et al. Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors. J Clin Oncol 33, 2015 (suppl; abstr 2512).
44. Ivanenkov YA, Chufarova NV. Small-molecule arginase inhibitors. Pharm Pat Anal 2014;3:65-85.